On Friday, Lyell Immunopharma Inc (NASDAQ: LYEL) opened higher 3.64% from the last session, before settling in for the closing price of $0.92. Price fluctuations for LYEL have ranged from $0.85 to $3.26 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 428.28% annually for the last half of the decade. Company’s average yearly earnings per share was noted 14.52% at the time writing. With a float of $125.06 million, this company’s outstanding shares have now reached $253.96 million.
In an organization with 224 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -23680.95%, operating margin of -348844.44%, and the pretax margin is -323792.06%.
Lyell Immunopharma Inc (LYEL) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Lyell Immunopharma Inc is 55.21%, while institutional ownership is 22.58%.
Lyell Immunopharma Inc (LYEL) Latest Financial update
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.17 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.2) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 14.52% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -7.90% during the next five years compared to -15.28% drop over the previous five years of trading.
Lyell Immunopharma Inc (NASDAQ: LYEL) Trading Performance Indicators
Check out the current performance indicators for Lyell Immunopharma Inc (LYEL). In the past quarter, the stock posted a quick ratio of 13.43. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4582.10.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.80, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.83 in one year’s time.
Technical Analysis of Lyell Immunopharma Inc (LYEL)
Let’s dig in a bit further. During the last 5-days, its volume was 1.74 million. That was better than the volume of 1.02 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 26.52%. Additionally, its Average True Range was 0.13.
During the past 100 days, Lyell Immunopharma Inc’s (LYEL) raw stochastic average was set at 9.35%, which indicates a significant decrease from 13.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 125.56% in the past 14 days, which was higher than the 106.56% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1934, while its 200-day Moving Average is $1.8236. However, in the short run, Lyell Immunopharma Inc’s stock first resistance to watch stands at $0.9887. Second resistance stands at $1.0275. The third major resistance level sits at $1.0718. If the price goes on to break the first support level at $0.9056, it is likely to go to the next support level at $0.8613. The third support level lies at $0.8225 if the price breaches the second support level.
Lyell Immunopharma Inc (NASDAQ: LYEL) Key Stats
There are currently 279,221K shares outstanding in the company with a market cap of 274.93 million. Presently, the company’s annual sales total 130 K according to its annual income of -234,630 K. Last quarter, the company’s sales amounted to 30 K and its income totaled -44,580 K.
